What type of cancer is successfully treated by genetically influenced medication due to a single mutation?

Chronic Myeloid Leukemia (CML) is effectively treated with targeted therapies that are beneficial due to a specific genetic mutation known as the Philadelphia chromosome. This mutation results from the fusion of the BCR and ABL genes, leading to the production of a tyrosine kinase that promotes cancer cell proliferation. Medications like imatinib (Gleevec) specifically target this mutated enzyme, demonstrating the concept of precision medicine, where treatment is tailored to the genetic profile of a disease. This targeted approach has significantly improved outcomes for patients with CML, showcasing how a single mutation can guide the development of effective treatments. Other cancers mentioned may involve genetic factors, but they do not have the same level of targeted treatment based on a single mutation as seen in CML.